1
|
Martín-Aragón S, Villar Á, Benedí J. Age-dependent effects of esculetin on mood-related behavior and cognition from stressed mice are associated with restoring brain antioxidant status. Prog Neuropsychopharmacol Biol Psychiatry 2016; 65:1-16. [PMID: 26290950 DOI: 10.1016/j.pnpbp.2015.08.007] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2015] [Revised: 08/06/2015] [Accepted: 08/12/2015] [Indexed: 12/20/2022]
Abstract
Dietary antioxidants might exert an important role in the aging process by relieving oxidative damage, a likely cause of age-associated brain dysfunctions. This study aims to investigate the influence of esculetin (6,7-dihydroxycoumarin), a naturally occurring antioxidant in the diet, on mood-related behaviors and cognitive function and its relation with age and brain oxidative damage. Behavioral tests were employed in 11-, 17- and 22-month-old male C57BL/6J mice upon an oral 35day-esculetin treatment (25mg/kg). Activity of antioxidant enzymes, GSH and GSSG levels, GSH/GSSG ratio, and mitochondrial function were analyzed in brain cortex at the end of treatment in order to assess the oxidative status related to mouse behavior. Esculetin treatment attenuated the increased immobility time and enhanced the diminished climbing time in the forced swim task elicited by acute restraint stress (ARS) in the 11- and 17-month-old mice versus their counterpart controls. Furthermore, ARS caused an impairment of contextual memory in the step-through passive avoidance both in mature adult and aged mice which was partially reversed by esculetin only in the 11-month-old mice. Esculetin was effective to prevent the ARS-induced oxidative stress mostly in mature adult mice by restoring antioxidant enzyme activities, augmenting the GSH/GSSG ratio and increasing cytochrome c oxidase (COX) activity in cortex. Modulation of the mood-related behavior and cognitive function upon esculetin treatment in a mouse model of ARS depends on age and is partly due to the enhancement of redox status and levels of COX activity in cortex.
Collapse
Affiliation(s)
- Sagrario Martín-Aragón
- Departamento de Farmacología, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.
| | - Ángel Villar
- Departamento de Farmacología, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain
| | - Juana Benedí
- Departamento de Farmacología, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain
| |
Collapse
|
2
|
Matos MJ, Vilar S, Gonzalez-Franco RM, Uriarte E, Santana L, Friedman C, Tatonetti NP, Viña D, Fontenla JA. Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study. Eur J Med Chem 2013; 63:151-61. [PMID: 23474901 DOI: 10.1016/j.ejmech.2013.02.009] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2012] [Revised: 02/04/2013] [Accepted: 02/08/2013] [Indexed: 01/02/2023]
Abstract
A series of (coumarin-3-yl)carbamates was synthesized and evaluated in vitro as monoamine oxidase (MAO-A and MAO-B) inhibitors. Most of the new compounds selectively inhibited MAO-B isoenzyme with IC50 values in the micro or nanoMolar ranges. Since these compounds must achieve the brain cells, theoretical evaluation of ADME properties were also carried out. Compound 8 (benzyl(coumarin-3-yl)carbamate), which presented the most interesting in vitro MAO-B inhibitory profile (IC50 against MAO-B = 45 nM), was subjected to further studies. This in vitro MAO-B inhibitory activity is comparable with that of the selegiline, the reference compound (IC50 against MAO-B = 20 nM). Taking into account the in vitro results of compound 8, in vivo assays and docking calculations were also carried out for this derivative.
Collapse
Affiliation(s)
- Maria J Matos
- Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Schulz D, Mirrione MM, Henn FA. Cognitive aspects of congenital learned helplessness and its reversal by the monoamine oxidase (MAO)-B inhibitor deprenyl. Neurobiol Learn Mem 2010; 93:291-301. [DOI: 10.1016/j.nlm.2009.11.003] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2009] [Revised: 10/30/2009] [Accepted: 11/15/2009] [Indexed: 10/20/2022]
|
4
|
Pardon MC, Hanoun N, Perez-Diaz F, Joubert C, Launay JM, Christen Y, Hamon M, Cohen-Salmon C. Long-term treatment with the antioxidant drug EGb 761 at senescence restored some neurobehavioral effects of chronic ultramild stress exposure seen in young mice. Neurobiol Aging 2004; 25:1067-83. [PMID: 15212832 DOI: 10.1016/j.neurobiolaging.2003.10.013] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2003] [Accepted: 10/24/2003] [Indexed: 11/25/2022]
Abstract
In this study, we compared the effects of chronic ultramild stress (CUMS) exposure on decision-making behavior in a validated test, and on the stress responsive serotoninergic and dopaminergic systems in four age groups of B6D2F1 female mice (5-6, 11-12, 17-18 and 23-24 months old). The levels of serotonin (5-HT) and its metabolite 5-hydroxyindolacetic acid (5-HIAA) were measured in the brain stem, the cortex, the striatum and the hippocampus; the levels of dopamine (DA) and its metabolite dihydroxyphenylacetic acid (DOPAC) were measured in the brain stem and the striatum. The influence of a long-term treatment with the extract of Ginkgo biloba leaves EGb 761 (Tanakan) on age- and stress-related changes was also investigated in the two oldest age groups. In the absence of drug treatment, middle-age mice were the least efficient in making a decision, and senescent mice exhibited reduced levels of both 5-HT and DA and their metabolites in all the brain areas examined. CUMS facilitated evaluation and choice behavior in all age groups, but induced age-dependent reduction of hesitation, acceleration of information processing and reduction in serotoninergic neurotransmission. In senescent mice, EGb 761 reduced the impact of stress on evaluation and hesitation, and restored some stress-related neurobehavioral changes that were only seen in young mice, i.e. acceleration of information processing and reduction in brain 5-HIAA levels. Restoration of some plasticity of the serotoninergic systems might contribute to the stress alleviating influence of EGb 761 in old age.
Collapse
Affiliation(s)
- M-C Pardon
- IFR 70 des Neurosciences, CNRS UMR 7593, Hôpital de La Salpêtrière, Pavillon Clérambault, 47 Bd de l'hôpital, 75651 Paris Cedex 13, France.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Kitani K, Minami C, Isobe KI, Maehara K, Kanai S, Ivy GO, Carrillo MC. Why (--)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mech Ageing Dev 2002; 123:1087-100. [PMID: 12044958 DOI: 10.1016/s0047-6374(01)00392-x] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
(--)Deprenyl, a monoamine oxidase B (MAO B) inhibitor is known to upregulate activities of anti-oxidant enzymes such as superoxide dismutase (SOD) and catalase (CAT) in brain dopaminergic regions. The drug is also the sole chemical which has been repeatedly shown to increase life spans of several animal species including rats, mice, hamsters and dogs. Further, the drug was recently found to enhance anti-oxidant enzyme activities not only in brain dopaminergic regions but also in extra-brain tissues such as the heart, kidneys, adrenal glands and the spleen. We and others have also observed mobilization of many humoral factors (interferone (INF)-gamma, tumor necrosis factor (TNF)-alpha, interleukine (IL)-1beta,2,6, trophic factors, etc.) and enhancement of natural killer (NK) cell functions by (-)deprenyl administration. An apparent extension of life spans of experimental animals reported in the past may be better explained by these new observations that (-)deprenyl upregulate SOD and CAT activities not only in the brain but also in extra-brain vital organs and involve anti-tumorigenic as well as immunomodulatory effect as well. These combined drug effects may lead to the protection of the homeostatic regulations of the neuro-immuno-endocrine axis of an organism against aging.
Collapse
Affiliation(s)
- Kenichi Kitani
- National Institute for Longevity Sciences, 36-3, Gengo, Morioka-cho, Obu-shi, Aichi 474-8522, Japan.
| | | | | | | | | | | | | |
Collapse
|
6
|
Knoll J. Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain. CNS DRUG REVIEWS 2001; 7:317-45. [PMID: 11607046 PMCID: PMC6494119 DOI: 10.1111/j.1527-3458.2001.tb00202.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Hundreds of millions of people now die over the age of 80 years primarily due to twentieth century progress in hygiene, chemotherapy, and immunology. With a longer average lifespan, the need to improve quality of life during the latter decades is more compelling. "Aging--The Epidemic of the New Millenium," a recent international conference (Monte Carlo, June 17-18, 2000), showed with peculiar clarity that a safe and efficient drug strategy to slow the age-related decay of brain performance is still missing. This review summarizes the physiologic and pharmacologic arguments in favor of a peculiar lifelong prophylactic medication with reasonable chances to keep in check brain aging and decrease the precipitation of age-related neurological diseases.
Collapse
Affiliation(s)
- J Knoll
- Department of Pharmacology, Faculty of General Medicine, Semmelweis University, H-1445 Budapest, Hungary.
| |
Collapse
|
7
|
Kitani K, Minami C, Maruyama W, Kanai S, Ivy GO, Carrillo MC. Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of (-)deprenyl. JOURNAL OF NEURAL TRANSMISSION. SUPPLEMENTUM 2001:139-56. [PMID: 11205136 DOI: 10.1007/978-3-7091-6301-6_9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
(-)Deprenyl has been reported to prolong the life span of different animal species. Further, the drug effectively increases antioxidant enzyme activities such as superoxide dismutase (SOD) and catalase (CAT) in brain dopaminergic regions. We have found that the effect of the drug on antioxidant enzyme activities is highly dose dependent, increasing with an increasing dose, however, a higher dose becomes less effective and an excessive dose becomes adversely effective. Most importantly, an optimal dose for the effect varies widely depending on animal species, strain, sex, age and duration of the treatment, which may at least partly explain discrepancies reported among different studies in the past. From the parallelism of the dose-effect relationship of the drug between life span extension and increasing endogenous antioxidant enzyme activity, we have suggested that the above two effects of (-)deprenyl may be causally related. This review summarizes our past series of studies and also reports our very recent observation that other propargylamines such as rasagiline and (R)-N-(2-heptyl)-N-methylpropagylamine (R-2HMP) also share the property of enhancing antioxidant enzyme activities. Further, our most recent study has found that these propargylamines increase antioxidant enzyme activities not only in brain dopaminergic regions but in extra-brain dopaminergic tissues such as the heart and kidneys. These observations are discussed in relation to the life prolonging effect of (-)deprenyl reported in the past.
Collapse
Affiliation(s)
- K Kitani
- National Institute for Longevity Sciences, Obu, Aichi, Japan.
| | | | | | | | | | | |
Collapse
|
8
|
Kitani K, Minami C, Yamamoto T, Maruyama W, Kanai S, Ivy GO, Carrillo MC. Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy. Ann N Y Acad Sci 2001; 928:248-60. [PMID: 11795516 DOI: 10.1111/j.1749-6632.2001.tb05654.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The free radical theory of aging was initially proposed by Harman half a century ago primarily to explain biological aging processes. Although administration of so-called antioxidant chemicals, which have been tested in the past for several decades, turned out to be mostly ineffective in prolonging the life spans of animals, the same theory of age-associated diseases appears to be increasingly supported in the last two decades. Despite these difficulties, the success in extending life span of 4 different animal species (mice, rats, hamsters, and dogs) with (-)deprenyl (including a study of our group) indicates that there might exist another type of antioxidant strategy in addition to a simple administration of antioxidant chemicals. (-)Deprenyl has also been shown to increase superoxide dismutase (SOD) and catalase (CAT) activities selectively in brain dopaminergic tissues. Interestingly, we have recently shown that another propargylamine, rasagiline not only increases antioxidant enzyme activities (CAT and SOD) in brain dopaminergic regions as (-)deprenyl does, but also increases CAT and SOD activities in extrabrain catecholaminergic systems such as the heart and kidneys as well. These recent observations coupled with previous observations on the life span of animals with (-)deprenyl suggest that pharmacological modulation of endogenous antioxidant enzyme activities could be one potential antioxidant strategy against aging and age-associated disorders. If the causal relationship between the two effects of (-)deprenyl exists as we hypothesized, we might be able to advance the elucidation of mechanism(s) of aging based on the free radical theory of aging.
Collapse
Affiliation(s)
- K Kitani
- National Institute for Longevity Sciences, Obu, Aichi, Japan.
| | | | | | | | | | | | | |
Collapse
|
9
|
Steyn SJ, Castagnoli K, Steyn S, Castagnoli N. Selective inhibition of MAO-B through chronic low-dose (R)-deprenyl treatment in C57BL/6 mice has no effect on basal neostriatal dopamine levels. Exp Neurol 2001; 168:434-6. [PMID: 11259132 DOI: 10.1006/exnr.2000.7610] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
C. Thiffault, L. Lamarre-Théroux, R. Quirion, and J. Poirier (1997, Mol. Brain Res. 44: 238-244) recently reported that chronic treatment of young (12 week old) C57BL/6 mice with (R)-deprenyl, a mechanism-based inactivator of monoamine oxidase B (MAO-B), leads to a more than fourfold increase in neostriatal dopamine levels. Such an effect could complicate the interpretation of results obtained from mechanistic studies designed to evaluate the putative neuroprotective effects of (R)-deprenyl in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mice. In contrast to the results of Thiffault et al., we have found that neostriatal dopamine levels in mature (32 week old) C57BL/6 mice were unaltered by chronic (R)-deprenyl treatment even though brain monoamine oxidase B activity was reduced by more than 80%. Neostriatal dopamine levels also were unaltered in both young and mature mice when the (R)-deprenyl treatment period was doubled compared to that reported by Thiffault et al. Consequently, studies on the putative neuroprotective properties of (R)-deprenyl in MPTP-lesioned mice are unlikely to be complicated by the possibility that inhibition of MAO-B alone will lead to an increase in neostriatal dopamine levels.
Collapse
Affiliation(s)
- S J Steyn
- Harvey W. Peters Center, Virginia Tech, Blacksburg, Virginia 24061-0212, USA
| | | | | | | |
Collapse
|
10
|
Pardon M, Pérez-Diaz F, Joubert C, Cohen-Salmon C. Age-dependent effects of a chronic ultramild stress procedure on open-field behaviour in B6D2F1 female mice. Physiol Behav 2000; 70:7-13. [PMID: 10978471 DOI: 10.1016/s0031-9384(00)00216-x] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Few studies have been devoted to the interaction between age and stress. However, in view of the age-related changes in various components of the stress responses, the effects of stress may not be constant with age. In this study, we used a dimensional approach to compare open-field behaviour of B6D2F1 female mice, aged 5-6, 11-12, 17-18 and 23-24 months, exposed to a chronic ultramild stress (CUMS) procedure, solely based on nonnociceptive socioenvironmental stressors. Three behavioural dimensions emerged from the principal-component analysis; these were labelled as motor reactivity, exploratory activity, and emotional reactivity. Despite a major effect of age on the three dimensions, we could not conclude that CUMS had any influence as a function the age of the subjects. At all ages, CUMS increased motor activity and had no clear-cut effect on emotional reactivity and exploratory activity. The results are discussed in terms of the influence of the nature of the stressors on behavioural responses to novelty.
Collapse
Affiliation(s)
- M Pardon
- UMR 7593 CNRS, Personnalité et Conduites Adaptatives, Université Paris VI, Hôpital de la Salpêtrière, 47 Bd de l'Hôpital, 75013, Paris, France
| | | | | | | |
Collapse
|
11
|
Pardon MC, Joubert C, Perez-Diaz F, Christen Y, Launay JM, Cohen-Salmon C. In vivo regulation of cerebral monoamine oxidase activity in senescent controls and chronically stressed mice by long-term treatment with Ginkgo biloba extract (EGb 761). Mech Ageing Dev 2000; 113:157-68. [PMID: 10714935 DOI: 10.1016/s0047-6374(99)00107-4] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
It is well recognized that Ginkgo biloba extract (EGb 761) exert beneficial effects against various age-related changes and is able to reduce the negative influence of stress. In view of the age-dependent increase in the activity of the B form of monoamine oxidase (MAO-B) and in view of the anti-stress action of EGb 761 hypothetically attributed to an inhibition of monoamine oxidase by this substance, we investigated the effects of long-term treatment with EGb 761 upon in vivo cerebral MAO-A and -B activities of stressed and unstressed 17- and 18-month-old mice. The stress was a 'chronic mild stress' regimen whose behavioral impact is known to be reduced by EGb 761. The results showed that: (1) EGb761 induced reductions in MAO activity in 18-month-old, but not in 17-month-old mice; the older animals having higher basal MAO activity; (2) in unstressed mice, EGb 761 appeared to reduce the age-induced increase in cerebral MAO activity; (3) MAO-A and -B activities of stressed and treated 18-month-old mice did not differ significantly from the levels observed in unstressed and untreated 17-month-old mice. These results may shed light on the anti-stress effects of Ginkgo biloba extract.
Collapse
Affiliation(s)
- M C Pardon
- UMR 7593 CNRS, Hôpital de la Salpêtrière, Paris, France
| | | | | | | | | | | |
Collapse
|
12
|
Knoll J, Yoneda F, Knoll B, Ohde H, Miklya I. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Br J Pharmacol 1999; 128:1723-32. [PMID: 10588928 PMCID: PMC1571822 DOI: 10.1038/sj.bjp.0702995] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
1. The brain constituents beta-phenylethylamine (PEA) and tryptamine enhance the impulse propagation mediated transmitter release (exocytosis) from the catecholaminergic and serotoninergic neurons in the brain ('catecholaminergic/serotoninergic activity enhancer, CAE/SAE, effect'). (-)Deprenyl (Selegiline) and (-)1-phenyl-2-propylaminopentane [(-)PPAP] are amphetamine derived CAE substances devoid of the catecholamine releasing property. 2. By changing the aromatic ring in PPAP we developed highly potent and selective CAE/SAE substances, structurally unrelated to the amphetamines. Out of 65 newly synthetized compounds, a tryptamine derived structure, (-)1-(benzofuran-2-yl)-2-propylaminopentane [(-)BPAP] was selected as a potential follower of (-)deprenyl in the clinic and as a reference compound for further analysis of the CAE/SAE mechanism in the mammalian brain. 3. (-)BPAP significantly enhanced in 0.18 micromol 1(-1) concentration the impulse propagation mediated release of [(3)H]-noradrenaline and [(3)H]-dopamine and in 36 nmol 1(-1) concentration the release of [(3)H]-serotonin from the isolated brain stem of rats. The amount of catecholamines and serotonin released from isolated discrete rat brain regions (dopamine from the striatum, substantia nigra and tuberculum olfactorium, noradrenaline from the locus coeruleus and serotonin from the raphe) enhanced significantly in the presence of 10(-12) - 10(-14) M (-)BPAP. BPAP protected cultured hippocampal neurons from the neurotoxic effect of beta-amyloid in 10(-14) M concentration. In rats (-)BPAP significantly enhanced the activity of the catecholaminergic and serotoninergic neurons in the brain 30 min after acute injection of 0.1 microg kg(-1) s.c. In the shuttle box, (-)BPAP in rats was about 130 times more potent than (-)deprenyl in antagonizing tetrabenazine induced inhibition of performance.
Collapse
Affiliation(s)
- J Knoll
- Department of Pharmacology, Semmelweis University of Medicine, P.O.B. 370, H-1445, Hungary
| | | | | | | | | |
Collapse
|
13
|
Shukitt-Hale B, Smith DE, Meydani M, Joseph JA. The effects of dietary antioxidants on psychomotor performance in aged mice. Exp Gerontol 1999; 34:797-808. [PMID: 10579639 DOI: 10.1016/s0531-5565(99)00039-x] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Male C57BL/6NIA mice were provided one of six different antioxidant diets: vitamin E, glutathione, vitamin E plus glutathione, melatonin, strawberry extract, or control, beginning at 18 months of age. A battery of motor tests--rod walk, wire hang, plank walk, and inclined screen-was administered either: 1) before dietary treatment and then 6 months later at 24 months of age: or 2) only after 6 months of dietary treatment at age 24 months. An untreated group of 4-month-old mice served as young controls. Psychomotor performance was lower in 18-month-old mice compared with 4-month-old mice in the rod walk, wire hang, and inclined screen tests; however, no further decline was seen from 18 to 24 months on any measure. Chronic dietary antioxidant treatments were not effective in reversing age-related deficits in psychomotor behavior, except for the glutathione diet on inclined screen performance. It seems that motor performance deteriorates profoundly with age, because deficits at 18 months of age were as severe as they were at 24 months, and these age-associated motor deficits may be difficult to reverse, even with antioxidant treatment.
Collapse
Affiliation(s)
- B Shukitt-Hale
- United States Department of Agriculture-Agricultural Research Service, Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA.
| | | | | | | |
Collapse
|
14
|
Shukitt-Hale B. The effects of aging and oxidative stress on psychomotor and cognitive behavior. AGE 1999; 22:9-17. [PMID: 23604386 PMCID: PMC3455411 DOI: 10.1007/s11357-999-0002-7] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Decrements in motor and cognitive function occur in aging, possibly due to oxidative stress-induced damage to the brain. Declines in antioxidant defense mechanisms have been postulated as a causative factor in these age-related decrements, however a clear link between oxidative stress (OS) and behavioral changes in aging has yet to be established. This review shows that age-validated psychomotor and cognitive tests are sensitive to behavioral deficits under different models of OS, including: 1) decreasing OS protection by depleting glutathione and then increasing the OS with dopamine; 2) 100% oxygen exposure; and 3) radiation. Furthermore, interventions that reduce OS result in concurrent improvements in age-associated behavioral deficits. Therefore, age-related changes in behavior may result from an inability to cope with OS that occurs throughout the life-span.
Collapse
Affiliation(s)
- Barbara Shukitt-Hale
- USDA, Human Nutrition Research Center on Aging at Tufts Univ., 711 Washington St, Rm 919, Boston, MA 02111
| |
Collapse
|
15
|
Kitani K, Kanai S, Ivy GO, Carrillo MC. Assessing the effects of deprenyl on longevity and antioxidant defenses in different animal models. Ann N Y Acad Sci 1998; 854:291-306. [PMID: 9928438 DOI: 10.1111/j.1749-6632.1998.tb09910.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Among many pharmaceuticals that have been tested for their effects on longevities of different animal rodents, deprenyl is unique in that its effects on longevity has been tested in at least four different animal species by independent research groups and that the effect has been postulated to be due to its effect of raising such antioxidant enzyme activities as superoxide dismutase (SOD) and catalase (CAT) in selective brain regions. Thus far, in all four species of animals examined (rats, mice, hamsters, and dogs), a positive effect was demonstrated, although the extent of its effect is quite variable. Our group has examined the effect on longevities in rats and mice and on antioxidant enzymes in rats, mice, and dogs. Although in rats of both sexes, we have obtained positive effects on longevity, two studies with different doses in mice did not reveal a significantly positive effect. We have observed, however, significantly positive effects on SOD (in Cu, Zn-, and Mn-) as well as CAT (but not glutathione peroxidase) activities in the brain dopaminergic system such as in the S. nigra and striatum (but not in hippocampus) in all rats, mice, and dogs, although the effects were quite variable, depending on the doses used. In mice, however, a long-term administration (3x/w, 3 months) caused a remarkable decrease in the magnitude of activity as well as a narrowing of the effective dose range, which may explain a relatively weak effect of the drug on mouse longevity. Further, a recent study on aging beagle dogs by Ruehl et al. showed a remarkable effect on longevity, which agrees with our SOD study in dogs. Although deprenyl has been claimed to have several other effects, such as a radical scavenging effect and a neuroprotective effect, past reports on its effects on longevities and antioxidant defenses are compatible with the notion that the drug prolongs the life span of animals by reducing the oxidative damage to the brain dopaminergic system during aging. Further, our studies on F-344 rats as well as a dog study by Ruehl et al. suggest that the drug may at least partially prolong the life span of animals by enhancing immune system function and preventing tumor development in animals.
Collapse
Affiliation(s)
- K Kitani
- National Institute for Longevity Sciences, Aichi, Japan.
| | | | | | | |
Collapse
|
16
|
Shukitt-Hale B, Mouzakis G, Joseph JA. Psychomotor and spatial memory performance in aging male Fischer 344 rats. Exp Gerontol 1998; 33:615-24. [PMID: 9789738 DOI: 10.1016/s0531-5565(98)00024-2] [Citation(s) in RCA: 115] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Psychomotor and spatial memory performance were examined in male Fischer 344 rats that were 6, 12, 15, 18, and 22 months of age, to assess these parameters as a function of age and to determine at what age these behaviors begin to deteriorate. Complex motor behaviors, as measured by rod walk, wire suspension, plank walk, inclined screen, and accelerating rotarod performance, declined steadily with age, with most measures being adversely affected as early as 12 to 15 months of age. Spatial learning and memory performance, as measured by the working memory version of the Morris water maze (MWM), showed decrements at 18 and 22 months of age (higher latencies on the working memory trial), with some change noticeable as early as 12-15 months of age (no improvement on the second trial following a 10-min retention interval); these differences were not due to swim speed. Therefore, complex motor and spatial memory behaviors show noticeable declines early in the lifespan of the male Fisher 344 rat. This cross-sectional age analysis study using the latest behavioral techniques determines the minimal age at which psychomotor and spatial learning and memory behaviors deteriorate; this information is important when planning for longitudinal studies where interventions are tested for their efficacy in preventing or restoring age-related behavioral deficits.
Collapse
Affiliation(s)
- B Shukitt-Hale
- USDA-ARS, Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts 02111, USA.
| | | | | |
Collapse
|
17
|
Rothblat DS, Schneider JS. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons. Brain Res 1998; 779:226-30. [PMID: 9473679 DOI: 10.1016/s0006-8993(97)01260-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The present study examined the effects of GM1 ganglioside and the monoamine oxidase B (MAO-B) inhibitor L-deprenyl, alone and in combination, on striatal dopamine (DA) and DOPAC levels, and the density of tyrosine hydroxylase (TH) positive neurons in the substantia nigra pars compacta (SNc) of C57bl/6J mice following MPTP administration (20 mg/kg, s.c., twice daily for 5 days). GM1 treatment (30 mg/kg, i.p., daily for 3 weeks, beginning 24 h after the last MPTP injection) partially restored striatal DA levels and rescued SNc neurons. A high dose of L-deprenyl, inhibiting MAO-B activity, (10 mg/kg, i.p. every other day for 3 weeks beginning 3 days after the last MPTP injection) increased striatal DA content, but did not rescue TH-positive SNc neurons. A low dose of L-deprenyl (0.01 mg/kg, i.p. every other day for 3 weeks beginning 3 days after the last MPTP injection) had no effect on either striatal neurochemistry or the rescue of SNc TH-positive neurons. Co-administration of GM1 and high dose L-deprenyl caused a synergistic increase in striatal DA levels, above that obtained with either GM1 or high dose L-deprenyl alone. Co-administration of GM1 and low dose L-deprenyl was not only not synergistic, but caused GM1s effects to be antagonized. The results do not confirm previous findings that low dose L-deprenyl administration in vivo after MPTP can rescue SNc neurons. Given GM1's potential as an adjunct to present anti-parkinsonian medications which include L-deprenyl, it will be important to further investigate the interactions between these two potential therapies.
Collapse
Affiliation(s)
- D S Rothblat
- Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
| | | |
Collapse
|
18
|
Abstract
In the past, structural changes in the brain with aging have been studied using a variety of animal models, with rats and nonhuman primates being the most popular. With the rapid evolution of mouse genetics, murine models have gained increased attention in the neurobiology of aging. The genetic contribution of age-related traits as well as specific mechanistic hypotheses underlying brain aging and age-related neurodegenerative diseases can now be assessed by using genetically-selected and genetically-manipulated mice. Against this background of increased demand for aging research in mouse models, relatively few studies have examined structural alterations with aging in the normal mouse brain, and the data available are almost exclusively restricted to the C57BL/6 strain. Moreover, many older studies have used quantitative techniques which today can be questioned regarding their accuracy. Here we review the state of knowledge about structural changes with aging in outbred, inbred, genetically-selected, and genetically-engineered murine models. Moreover, we suggest several new opportunities that are emerging to study brain aging and age-related neurodegenerative diseases using genetically-defined mouse models. By reviewing the literature, it has become clear to us that in light of the rapid progress in genetically-engineered and selected mouse models for brain aging and age-related neurodegenerative diseases, there is a great and urgent need to study and define morphological changes in the aging brain of normal inbred mice and to analyze the structural changes in genetically-engineered mice more carefully and completely than accomplished to date. Such investigations will broaden knowledge in the neurobiology of aging, particularly regarding the genetics of aging, and possibly identify the most useful murine models.
Collapse
Affiliation(s)
- M Jucker
- Gerontology Research Centre, Nathan W. Shock Laboratories, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
| | | |
Collapse
|
19
|
Stoll S, Hafner U, Kränzlin B, Müller WE. Chronic treatment of Syrian hamsters with low-dose selegiline increases life span in females but not males. Neurobiol Aging 1997; 18:205-11. [PMID: 9258898 DOI: 10.1016/s0197-4580(97)00009-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The only intervention conclusively shown to prolong life span in mammals is caloric restriction. Selegiline, a selective, irreversible inhibitor of monoamine oxidase B (MAO-B), is the first drug reported to reproducibly increase mean and maximum life span in animals, although this has only been demonstrated in male rats and mice. The effect on life span is commonly assumed to depend on MAO-B inhibition, but final experimental proof is missing. Therefore, we investigated the possible relationship between selegiline's effect on life span and MAO-B by monitoring survival data and MAO activity in Syrian hamsters of both sexes. Selegiline (0.05 mg/kg) significantly increased life span in female Syrian hamsters, but not in males. In contrast, MAO-B was inhibited equally in both sexes by about 40%, although females had a higher baseline MAO-B activity. No increase in MAO-B with age was observed. Female control hamsters had a shorter life span than male controls. Interestingly, this sex difference disappeared in the selegiline-treated animals. These findings suggest that the increase of life span by selegiline might be independent of MAO-B inhibition, but is possibly related to mechanisms determining sex differences of life span.
Collapse
Affiliation(s)
- S Stoll
- Central Institute of Mental Health, Department of Psychopharmacology, Mannheim, Germany
| | | | | | | |
Collapse
|
20
|
Carrillo MC, Kitani K, Kanai S, Sato Y, Ivy GO, Miyasaka K. Long term treatment with (-)deprenyl reduces the optimal dose as well as the effective dose range for increasing antioxidant enzyme activities in old mouse brain. Life Sci 1996; 59:1047-57. [PMID: 8809224 DOI: 10.1016/0024-3205(96)00420-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
C57BL mice of the male sex received different doses of (-)deprenyl (0.25, 0.5, 1.0 mg/kg per injection 3 times a week, s.c.) for 3 months beginning at the age of 26 months. At the age of 29 months, animals were sacrificed and superoxide dismutase (SOD) and catalase (CAT) activities were examined in several brain regions. The dose of 0.5 mg/kg (3 times a week) was most effective in increasing SOD and CAT activities in S. nigra, striatum and cerebral cortex but not in hippocampus or cerebellum. The dose of 0.25 mg/kg was also effective in increasing enzyme activities, but the effect was much lower than the dose of 0.5 mg/kg. The magnitudes of increase in enzyme activities with the dose of 0.5 mg/kg, however, were generally much lower than respective values we previously found in animals treated with (-)deprenyl for only 3 weeks. The highest dose of 1.0 mg/kg had negligible effect. Enzyme activities in all groups of animals that were examined 2 weeks after the last (-)deprenyl dose were practically the same as respective control values. Together with the results from our previous study with short term (-)deprenyl treatment in old mice, these results replicate our previous findings in old female rats. We showed that longer term treatment with (-)deprenyl reduces the optimal dose for increasing antioxidant enzyme activities by a factor of 5 to 10. The present study further indicates that longer term treatment with (-)deprenyl also reduces the effective dose range of (-)deprenyl as well as the magnitude of increase of enzyme activities. If the effect of (-)deprenyl for increasing these antioxidant enzyme activities in selective brain regions is causally related to its effect of increasing average life expectancies of animals, the selection of a proper dose of the drug may be a critical factor for life span studies in which the drug, is administered for more than one year.
Collapse
Affiliation(s)
- M C Carrillo
- Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Japan
| | | | | | | | | | | |
Collapse
|
21
|
de la Cruz CP, Revilla E, Steffen V, Rodríguez-Gómez JA, Cano J, Machado A. Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl. Br J Pharmacol 1996; 117:1756-60. [PMID: 8732287 PMCID: PMC1909550 DOI: 10.1111/j.1476-5381.1996.tb15350.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
1. We have studied the effect of (-)-deprenyl on the oxidative damage that the rat substantia nigra suffers during aging. 2. (-)-Deprenyl (2 mg kg-1, three times a week) administered for two months, beginning at 22 months of age, produced a significant increase in tyrosine hydroxylase (TH) activity (2.67 +/- 0.40 and 3.64 +/- 0.38 nmol mg-1 protein h-1 in untreated aged rats and treated aged rats respectively, P < 0.05) and in TH amount (0.072 +/- 0.012 and 0.128 +/- 0.38 absorbance 405 nm in untreated aged and treated aged rats respectively, P < 0.05). 3. The proteins of aged rat substantia nigra showed a significant decrease of carbonyl groups in treated animals compared with saline-injected control rats (136.2 +/- 21.8 and 71.5 +/- 13.2 c.p.m. microgram-1 protein in untreated aged and treated aged rats respectively, P < 0.05). 4. The carbonyl groups measured in TH enzyme showed a statistically significant decrease (42.3%) after (-)-deprenyl treatment (471.4 +/- 73.0 and 271.9 +/- 50.00 c.p.m. in untreated aged and treated aged rats respectively, P < 0.001). 5. All these results suggest that oxidative damage produced during aging is prevented by (-)-deprenyl treatment and could explain the effect of this drug in Parkinson's disease (PD) and other degenerative diseases such as Alzheimer's disease.
Collapse
Affiliation(s)
- C P de la Cruz
- Departamento de Bioquímica, Bromatología y Toxicología, Facultad de Farmacia, Universidad de Sevilla, Spain
| | | | | | | | | | | |
Collapse
|
22
|
Bensoula AN, Guastavino JM, Lalonde R, Portet R, Bertin R, Krafft B. Spatial navigation of staggerer and normal mice during juvenile and adult stages. Physiol Behav 1995; 58:823-5. [PMID: 8577876 DOI: 10.1016/0031-9384(95)00101-n] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Staggerer mutant mice were compared to normal mice of two different ages (2-6 mo) in two tasks requiring navigational skills in a circular maze visible platform condition and a T-maze. Staggerer mutants had higher latencies than normal mice in both tests. The performance of normal mice worsened with age for both tests. The aging factor interacted with the genotype factor only in the circular maze, where the mutant-nonmutant differential was wider among juvenile animals. In neither task was there evidence of a more pronounced impairment with aging in staggerer mutants. It remains to be determined in this mutant at more advanced stages of aging or in other models of chronic neural disease whether early neuropathology accelerates brain aging.
Collapse
Affiliation(s)
- A N Bensoula
- Université de Nancy 1, Laboratorie de Biologie et Physiologie du Comportement, URA CNRS 1293, Vandoeuvre-les-Nancy, France
| | | | | | | | | | | |
Collapse
|
23
|
Gupta M, Wiener HL. Effects of deprenyl on monoamine oxidase and neurotransmitters in the brains of MPTP-treated aging mice. Neurochem Res 1995; 20:385-9. [PMID: 7544444 DOI: 10.1007/bf00973091] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Deprenyl is a selective monoamine oxidase B (MAO-B) inhibitor and has been used in the treatment of Parkinson's disease. However, it is not known whether deprenyl effects are symptomatic or pharmacological. Aging mice were partially lesioned with MPTP. Control and MPTP-treated mice were given deprenyl in drinking water for 14 days. Brain tissue (including the striatum, olfactory tubercle and cerebral cortex) was assayed for MAO-B and neurotransmitter levels. The results show that deprenyl treatment, given alone or after MPTP, reduced MAO-B activity in all the three regions. No change was seen in dopamine (DA), 3,4-dihydroxyphenyl acetic acid (DOPAC), and homovanillic acid (HVA) content in any of the three areas. Cortical norepinephrine (NE) levels were also unaltered. However, striatal serotonin (5-HT) levels were decreased while its metabolite, 5-HIAA levels were significantly increased in the olfactory tubercle in animals receiving deprenyl alone. These data suggest that deprenyl treatment reduces MAO-B activity in regions in addition to the striatum without affecting norepinephrine, dopamine (DA) and its metabolites.
Collapse
Affiliation(s)
- M Gupta
- Department of Anatomical Sciences and Neurobiology, University of Louisville School of Medicine, Kentucky 40292, USA
| | | |
Collapse
|
24
|
Amenta F, Bograni S, Cadel S, Ferrante F, Valsecchi B, Vega JA. Microanatomical changes in the frontal cortex of aged rats: effect of L-deprenyl treatment. Brain Res Bull 1994; 34:125-31. [PMID: 8044686 DOI: 10.1016/0361-9230(94)90008-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The present study was designed to assess whether treatment with L-deprenyl has any effect on the age-related microanatomical changes in the rat frontal cortex. Male Sprague-Dawley rats of 19 months of age were treated until the 24th month with an oral daily dose of 1.25 mg/kg or of 5 mg/kg of L-deprenyl. Eleven-month-old untreated rats were used as an adult reference group. The density of nerve cell profiles and of glial fibrillary acidic protein-(GFAP) immunoreactive astroglial profiles, lipofuscin accumulation within the cytoplasm of pyramidal neurons, and MAO-B reactivity were assessed. A decreased density of nerve cell profiles and an increased density of astroglial profiles as well as augmented lipofuscin deposition and MAO-B reactivity were observed in the frontal cortex of rats of 24 months in comparison with 12-month-old animals. In the frontal cortex of rats treated with 5 mg/kg/day L-deprenyl, which is a dose inhibiting MAO-B activity, the density of nerve cell and GFAP-immunoreactive astrocyte profiles is increased and decreased respectively in comparison with age-matched untreated subjects. Lipofuscin deposition is reduced. The lower dose of L-deprenyl (1.25 mg/kg/day) which did not affect MAO-B activity, decreased lipofuscin deposition but was without effect on the density of nerve cell or GFAP-immunoreactive astrocyte profiles. The above findings suggest that treatment with L-deprenyl is able to counter some microanatomical changes occurring in the frontal cortex of aged rats. Some of these effects are probably not related to the inhibitory MAO-B activity of the compound.
Collapse
Affiliation(s)
- F Amenta
- Sezione di Anatomia Umana, Università di Camerino, Italy
| | | | | | | | | | | |
Collapse
|